Compare Novavax Inc (NVAX) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Simon Property Group Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Simon Property Group Inc trades at $199.42 (market cap $64.59B). The key difference: Simon Property Group Inc is far larger — about 35.5× Novavax Inc's market cap, and Simon Property Group Inc pays a 4.46% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Simon Property Group Inc for 99 Days on average.
| NVAX | SPG | |
|---|---|---|
Market Cap | $1.82B | $64.59B |
Volume | 6,198,505 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $12.56 | $236.70 |
52-Week Low | $6.22 | $173.35 |
Typical Hold Time | 59 Days | 99 Days |
Enterprise Value | $1.39B | $93.03B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Simon Property Group (SPG) trades at $199.61, up 1.02% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results, including revenue of $6.36B and net income of $4.63B, with a net margin of 72.7%. Recent news highlights leasing demand strength and a new media network launch, while analysts maintain a consensus price target of $222.90.
SPG offers value with a P/E of 14.09 and robust profitability, but faces risks from high debt levels and interest rate sensitivity. The stock's upside potential hinges on sustained retail demand and effective debt management, with institutional sentiment leaning neutral amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
